» Articles » PMID: 29707124

and Mutation Status Associates with and Expression in Ovarian Cancer

Overview
Journal Oncotarget
Specialty Oncology
Date 2018 May 1
PMID 29707124
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Checkpoint molecules such as programmed cell death protein-1 (PD-1) and its ligand PD-L1 are critically required for tumor immune escape. The objective of this study was to investigate tumoral and mRNA-expression in a cohort of ovarian cancer (OC) patients in relation to tumor mutations. We analyzed mRNA expression of , and by quantitative real-time PCR in tissue of 170 patients with low grade-serous (LGSOC), high-grade serous (HGSOC), endometrioid and clear cell OC compared to 28 non-diseased tissues (ovaries and fallopian tubes) in relation to tumor protein 53 () and breast cancer gene 1/2 () mutation status. -mutated OC strongly expressed compared to wild-type OC ( = 0.028) and -mutated OC increasingly expressed ( = 0.024) and ( = 0.012) compared to wild-type OC. For the first time in human, we noted a strong correlation between tumoral and or mRNA-expression, respectively ( < 0.001). OC tissue increasingly expressed compared to healthy controls (vs. ovaries: < 0.001; vs. tubes: = 0.018). and mRNA-expression increased with higher tumor grade ( = 0.008 and = 0.027, respectively) and younger age (< median age, = 0.001). Finally, in the major subgroup of our cohort, FIGO stage III/IV HGSOC, high and mRNA-expression was associated with reduced progression-free ( = 0.024) and overall survival ( = 0.049) but only in the univariate analysis. Our study suggests that in OC / mRNA-expression is controlled by and affected by and mutations. We suggest that these mutations might serve as potential predictive factors that guide anti-/ immunotherapy.

Citing Articles

Thirty Years of BRCA1: Mechanistic Insights and Their Impact on Mutation Carriers.

Moser S, Jonkers J Cancer Discov. 2025; 15(3):461-480.

PMID: 40025950 PMC: 11893084. DOI: 10.1158/2159-8290.CD-24-1326.


EML4-ALK-Positive Ovarian Cancer With Intracranial Metastasis Responds to Lorlatinib: A Case Report and Literature Review.

Li Q, Cai T, Zheng X, Zhang S, Li C, Tang H Clin Case Rep. 2025; 13(1):e70043.

PMID: 39780907 PMC: 11707256. DOI: 10.1002/ccr3.70043.


BRCA1 and BRCA2: from cancer susceptibility to synthetic lethality.

Khalizieva A, Moser S, Bouwman P, Jonkers J Genes Dev. 2024; 39(1-2):86-108.

PMID: 39510841 PMC: 11789497. DOI: 10.1101/gad.352083.124.


Tumoral programmed cell death 1 (PD1) expression in endometrial carcinoma is a prognostic marker for patient outcome.

Feroz B, Pan T, Leitner K, Ebner C, Steger K, Kildal W Int J Gynecol Cancer. 2024; 34(11):1711-1718.

PMID: 38969503 PMC: 11671916. DOI: 10.1136/ijgc-2023-005188.


Characterization and prognostic impact of ACTBL2-positive tumor-infiltrating leukocytes in epithelial ovarian cancer.

Topalov N, Mayr D, Kuhn C, Leutbecher A, Scherer C, Kraus F Sci Rep. 2023; 13(1):22620.

PMID: 38114558 PMC: 10730610. DOI: 10.1038/s41598-023-49286-9.


References
1.
Loke P, Allison J . PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A. 2003; 100(9):5336-41. PMC: 154346. DOI: 10.1073/pnas.0931259100. View

2.
Mittica G, Genta S, Aglietta M, Valabrega G . Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?. Int J Mol Sci. 2016; 17(7). PMC: 4964540. DOI: 10.3390/ijms17071169. View

3.
Bieche I, Franc B, Vidaud D, Vidaud M, Lidereau R . Analyses of MYC, ERBB2, and CCND1 genes in benign and malignant thyroid follicular cell tumors by real-time polymerase chain reaction. Thyroid. 2001; 11(2):147-52. DOI: 10.1089/105072501300042802. View

4.
Zhang L, Conejo-Garcia J, Katsaros D, Gimotty P, Massobrio M, Regnani G . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3):203-13. DOI: 10.1056/NEJMoa020177. View

5.
Lee J, Cimino-Mathews A, Peer C, Zimmer A, Lipkowitz S, Annunziata C . Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A.... J Clin Oncol. 2017; 35(19):2193-2202. PMC: 5493052. DOI: 10.1200/JCO.2016.72.1340. View